^
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
EHA 2022 - 2 weeks (NewA2)
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New C3)
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
venetoclax Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
venetoclax Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
venetoclax Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
acalabrutinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
acalabrutinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
acalabrutinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
acalabrutinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
BTK C481
|
CLL
|
BTK C481
|
CLL
|
LOXO-305 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
LOXO-305 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
iFCG Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
iFCG Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
SF3B1 mutation
|
CLL
|
SF3B1 mutation
|
CLL
|
venetoclax Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BCL2 D103Y
|
CLL
|
BCL2 D103Y
|
CLL
|
venetoclax + obinutuzumab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax + obinutuzumab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BCL2 G101V
|
CLL
|
BCL2 G101V
|
CLL
|
venetoclax + rituximab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax + rituximab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BCL2 G101V
|
CLL
|
BCL2 G101V
|
CLL
|
venetoclax + obinutuzumab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax + obinutuzumab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BCL2 D103Y
|
CLL
|
BCL2 D103Y
|
CLL
|
venetoclax + rituximab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax + rituximab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
venetoclax Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD20 positive
|
CLL
|
CD20 positive
|
CLL
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
orelabrutinib Sensitive: A1 - Approval
|
orelabrutinib Sensitive: A1 - Approval
|
CD20 expression
|
CLL
|
CD20 expression
|
CLL
|
rituximab-arrx Sensitive: A1 - Approval
|
rituximab-arrx Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
|
Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
venetoclax + rituximab Sensitive: A1 - Approval
|
venetoclax + rituximab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
ibrutinib + obinutuzumab Sensitive: A1 - Approval
|
ibrutinib + obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
obinutuzumab Sensitive: A1 - Approval
|
obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
ofatumumab Sensitive: A1 - Approval
|
ofatumumab Sensitive: A1 - Approval
|
CD20 positive
|
CLL
|
CD20 positive
|
CLL
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
venetoclax Sensitive: A1 - Approval
|
venetoclax Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab/hyaluronidase Sensitive: A1 - Approval
|
rituximab / hyaluronidase Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
obinutuzumab + acalabrutinib Sensitive: A1 - Approval
|
obinutuzumab + acalabrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
obinutuzumab Sensitive: A1 - Approval
|
obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
acalabrutinib Sensitive: A1 - Approval
|
acalabrutinib Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab + idelalisib Sensitive: A1 - Approval
|
rituximab + idelalisib Sensitive: A1 - Approval
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
rituximab + idelalisib Sensitive: A1 - Approval
|
rituximab + idelalisib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
alemtuzumab Sensitive: A1 - Approval
|
alemtuzumab Sensitive: A1 - Approval
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab + idelalisib Sensitive: A1 - Approval
|
rituximab + idelalisib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
duvelisib Sensitive: A1 - Approval
|
duvelisib Sensitive: A1 - Approval
|
CD20 positive
|
CLL
|
CD20 positive
|
CLL
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
bendamustine Sensitive: A1 - Approval
|
bendamustine Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
bendamustine RTD Sensitive: A1 - Approval
|
bendamustine RTD Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
PCR Sensitive: A2 - Guideline
|
PCR Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ofatumumab Sensitive: A2 - Guideline
|
ofatumumab Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
FCR Sensitive: A2 - Guideline
|
FCR Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
zanubrutinib Sensitive: A2 - Guideline
|
zanubrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
zanubrutinib Sensitive: A2 - Guideline
|
zanubrutinib Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
Chr del(11q)
|
CLL
|
Chr del(11q)
|
CLL
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
Chr del(11q)
|
CLL
|
Chr del(11q)
|
CLL
|
rituximab Resistant: A2 - Guideline
|
rituximab Resistant: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
ofatumumab Resistant: A2 - Guideline
|
ofatumumab Resistant: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
chlorambucil Sensitive: A2 - Guideline
|
chlorambucil Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
CD20 inhibitor + bendamustine Sensitive: A2 - Guideline
|
CD20 inhibitor + bendamustine Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
TP53 deletion
|
CLL
|
TP53 deletion
|
CLL
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
TP53 deletion
|
CLL
|
TP53 deletion
|
CLL
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
TP53 deletion
|
CLL
|
TP53 deletion
|
CLL
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
alemtuzumab Sensitive: A2 - Guideline
|
alemtuzumab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
alemtuzumab Sensitive: A2 - Guideline
|
alemtuzumab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
pembrolizumab + nivolumab + ibrutinib Sensitive: A2 - Guideline
|
pembrolizumab + nivolumab + ibrutinib Sensitive: A2 - Guideline
|
BTK C481S
|
CLL
|
BTK C481S
|
CLL
|
acalabrutinib Resistant: A2 - Guideline
|
acalabrutinib Resistant: A2 - Guideline
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
FCR Sensitive: A2 - Guideline
|
FCR Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
Chr del(11q)
|
CLL
|
Chr del(11q)
|
CLL
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
duvelisib Sensitive: A2 - Guideline
|
duvelisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
pembrolizumab + ibrutinib Sensitive: A2 - Guideline
|
pembrolizumab + ibrutinib Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
duvelisib Sensitive: A2 - Guideline
|
duvelisib Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
OFAR Sensitive: A2 - Guideline
|
OFAR Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
R-CVAD Sensitive: A2 - Guideline
|
R-CVAD Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
EPOCH-R Sensitive: A2 - Guideline
|
EPOCH-R Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
R-CHOP Sensitive: A2 - Guideline
|
R-CHOP Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
BR Sensitive: A2 - Guideline
|
BR Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
BR + ibrutinib Sensitive: A2 - Guideline
|
BR + ibrutinib Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
BR + idelalisib Sensitive: A2 - Guideline
|
BR + idelalisib Sensitive: A2 - Guideline
|
TP53 wild-type
|
CLL
|
TP53 wild-type
|
CLL
|
zanubrutinib Sensitive: A2 - Guideline
|
zanubrutinib Sensitive: A2 - Guideline
|
Chr del(11)(q22.3)
|
CLL
|
Chr del(11)(q22.3)
|
CLL
|
ibrutinib Sensitive: B - Late Trials
|
ibrutinib Sensitive: B - Late Trials
|
